FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Muehler Andreas 2. Date of Event Requiring Statement (MM/DD/YYYY)
3/10/2021 

3. Issuer Name and Ticker or Trading Symbol IMMUNIC, INC. [IMUX]
(Last)       (First)       (Middle)
1200 AVENUE OF THE AMERICAS, SUITE 200
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
Chief Medical Officer /
(Street)
NEW YORK, NY 10036      
(City)             (State)             (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock  284480  I  See footnote (1)
Common Stock  10006  D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option   (2) 3/1/2031  Common Stock  65000  $15.72  D   
Stock Option   (3) 7/1/2030  Common Stock  44000  $12.30  D   
Stock Option   (4) 8/12/2029  Common Stock  10000  $13.34  D   
Stock Option   (5) 8/1/2029  Common Stock  30000  $13.29  D   

Explanation of Responses:
(1)  The Reporting Person is Director of Xanomed GmbH, which is the record holder of 284,480 shares of common stock of the Issuer, and exercises voting and dispositive power over such shares.
(2)  16,250 of the shares underlying the option vest on the first anniversary of the grant date. Thereafter, 1,360 of the underlying shares vest on the thirteen month anniversary of the grant date and 1,354 of the underlying shares vest on each successive one-month anniversary thereafter for the next 35 months.
(3)  11,000 of the shares underlying the option vest on the first anniversary of the grant date. Thereafter, 940 of the underlying shares vest on the thirteen month anniversary of the grant date and 916 of the underlying shares vest on each successive one-month anniversary thereafter for the next 35 months.
(4)  2,500 of the shares underlying the option vest on the first anniversary of the grant date. Thereafter, 220 of the underlying shares vest on the thirteen month anniversary of the grant date and 208 of the underlying shares vest on each successive one-month anniversary thereafter for the next 35 months.
(5)  7,500 of the shares underlying the option vest on the first anniversary of the grant date, with the remainder vesting in equal increments on each successive one-month anniversary thereafter for the next 36 months.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Muehler Andreas
1200 AVENUE OF THE AMERICAS, SUITE 200
NEW YORK, NY 10036


Chief Medical Officer

Signatures
/s/ Andreas Muehler 3/15/2021
**Signature of Reporting Person Date